Objective: To analyze the association between chronic hepatitis C virus (HCV) and cytomegalovirus (CMV) infections with type 2 diabetes in HIV-infected patients.
INTRODUCTION
Antiretroviral therapy has significantly reduced HIVassociated morbidity and mortality. 1 However, the substantially increased survival has exposed the HIV-infected population to a relevant number of co-morbid conditions, such as metabolic and cardiovascular disorders, 2 and to the long-term consequences of chronic co-infections, including chronic hepatitis C virus (HCV) infection. 3 Among the metabolic disorders, type 2 diabetes affects a relevant number of persons living with HIV. Although diabetes mellitus does not seem more frequent in HIV-infected subjects than in negative controls, 4 in the HIV-infected population diabetes represents a risk factor for all specific causes of death except non-AIDS cancers. 5 Moreover, exposure to some antiretroviral agents may also favor the emergence of type 2 diabetes. [6] [7] [8] In any case, the clinical impact of diabetes, as a risk factor for cardiovascular and cerebrovascular disorders, may be more relevant in the HIV-infected population where the incidence of cardiovascular disease is already increased as compared to the age-matched general population. 2 Chronic viral infections lead to immune activation and may therefore cause a number of co-morbidities. Indeed, chronic HCV infection, apart from causing liver-related morbidity and mortality, is also associated with an increased incidence of extra-hepatic disorders, including diabetes and cardiovascular disease, in the HIV-negative population. 9, 10 In HCV-infected patients, HIV co-infection has been associated with an accelerated liver disease. 3 Whether HCV co-infection favors the emergence of diabetes in HIV-infected patients remains to be fully established. Some reports indicate a similar incidence of type 2 diabetes in HCV-antibodypositive HIV-infected patients 11, 12 while other studies indicate that HCV-antibody-positive individuals have an increased risk. 4, 10 However, it is not clear whether HCVantibody positivity is a marker for a specific population exposed to a higher risk of diabetes due to behavioral factors or whether HCV infection by itself represents a risk factor for this disorder. In addition, latent cytomegalovirus (CMV) infection, as determined by a positive CMV-antibody serostatus, has been associated with an increased incidence of non-AIDS events, particularly cardiovascular events, 13 because of an immune activation mechanism. Latent CMV infection has also been associated with diabetes mellitus. 14 Aim of our study was to determine the impact of HCV infection, both as prior HCV exposure and as active HCV infection, and of latent CMV infection on the incidence and the prevalence of type 2 diabetes in a nationally representative Italian cohort of HIV-infected individuals.
PATIENTS AND METHODS
Patient selection for the incidence and prevalence analysis and definition of type 2 diabetes.
For the incident type 2 diabetes analysis, patients enrolled in the ICONA Foundation Study cohort 15 were selected who (1) had an available CMV IgG result (time of first result = baseline) and (2) did not have diabetes at baseline. For the prevalent type 2 diabetes analysis, all ICONA enrollees were evaluated at the date of diabetes diagnosis or at their last available follow-up, whichever occurred first. Type 2 diabetes was defined by one of the following criteria: (1) diagnosis by the treating clinician, (2) use of antidiabetic drugs, or (3) first of 2 consecutive blood glucose levels .125 mg/dL at a verified fasting status. All the type 2 diabetes diagnoses were validated by an external monitor using the above criteria.
Statistical Analysis
We used standard descriptive statistics to describe characteristics at baseline for the population analyzed for the diabetes incidence and at the date of diabetes diagnosis or last available follow-up for the population analyzed for the diabetes prevalence. Time to diagnosis of diabetes was analyzed using the Kaplan-Meier method using the time of first CMV serology as baseline. Patients were followed until onset of type 2 diabetes, last available clinical follow-up, death or September 30, 2014, whichever occurred first. Predictors of incident type 2 diabetes were analyzed by Poisson regression. In the multivariable model, we included variables with P , 0.10 at univariate analysis plus CMV serostatus. The type of antiretroviral treatment regimen used was analyzed as time updated variable.
Factors associated with prevalent type 2 diabetes at the last available follow-up were analyzed by logistic regression; multivariable models included variables with P , 0.10 at univariate analysis.
RESULTS

Incidence Analysis
Six thousand five hundred five patients were suitable for the type 2 diabetes incidence analysis. Baseline patients characteristics are summarized in Table 1 (left part) .
CMV IgG were detected in 84.4% of 6,505, HCVantibodies in 31.5% of 6112 tested, of whom 83.5% of 1033 tested had a detectable HCV RNA. During 38.062 personyears of follow-up (PYFU), we observed 140 cases of incident type 2 diabetes with an incidence rate of 3.7 (95% CI: 3.1 to 4.3) per 1.000 PYFU. Time-to-event analysis showed that the 5-years, 10-years, and 15-years estimated probability of type 2 diabetes were 1.8% (95% CI: 1.5 to 2.3), 3.4% (2.8-4.1) and 5.4% (4.4-6.7) , respectively ( Fig. 1) . By multivariable Poisson regression analysis (Table 2) , HCV RNA-positive status, but not HCV-antibody positive, HCV RNA negative status was independently associated with a higher incidence of type 2 diabetes as compared to an HCV-antibody negative status [adjusted relative rate, ARR, 1.73 (1.08-2.78)]; CMV IgG serology was not associated with incident diabetes. Other independent predictors of diabetes onset were male gender, older age, a higher baseline BMI, higher baseline glucose and triglycerides levels, presence of arterial hypertension, current use of a regimen containing NRTIs with an unboosted protease inhibitor (as compared with NRTI with NNRTI), and current use of stavudine+lamivudine as compared to tenofovir + emtricitabine ( Table 2 ).
Prevalence Analysis
Prevalent type 2 diabetes analysis was performed on 12,001 patients at their last follow-up in ICONA. Characteristics of the patients used in the prevalence analysis are summarized in Table 1 (right side). HCV antibodies were detected in 29.3% of 10,611 tested, whereas HCV RNA was detectable in 75.1% of 1095 tested; CMV IgG were positive in 84.6% of 7033 tested. Three hundred six patients (2.5%) had a diagnosis of type 2 diabetes at last follow-up. Factors associated with prevalent diabetes are summarized in Table 3 . Again, HCV RNA-positive status [adjusted odds ratio, AOR 2.49 (1.08-5.74)] was independently associated with prevalent type 2 diabetes, whereas HCV-antibody-positive, HCV 
DISCUSSION
In this cohort study, we observed how, in HIV-infected patients, active HCV replication was independently associated both with incident and prevalent type 2 diabetes. Interestingly, this association was not observed in HCVseropositive individuals without active HCV replication. This association was independent from several confounders including ALT or AST in both incident and prevalent diabetes analysis.
Our findings contribute to resolve the contradictory observations made in the HIV-positive and HIV-negative population, where the association between HCV and diabetes was mostly studied using HCV antibody status as marker of HCV infection. Indeed, an association was observed in some studies 4, 10 but not confirmed in others. 11, 12 In the HIVinfected population, approximately 80%-85% of HCVantibody-positive patients show a detectable serum HCV RNA. The proportion of HCV-antibody-positive patients without active HCV replication is deemed to increase because of the spread of highly effective HCV eradication therapies with direct acting antivirals. 16 Given the observed association with active HCV replication but not with simple HCVantibody-positive status, our study reinforces the hypothesis that HCV infection and replication per se and not its associated behavioral or biological factors are directly involved in the pathogenesis of type 2 diabetes. Several biological mechanisms have been hypothesized through which HCV infection may favor type 2 diabetes. HCV infection is thought to induce insulin resistance through multiple mechanisms, involving both the liver and peripheral tissues. 17, 18 Some of these mechanisms lead to an increased production of proinflammatory cytokines (such as TNF alpha and interleukin 6), 19 others result in the induction of liver steatosis, which is more prevalent in patients infected with HCV genotype 3. 20 In this study, we were unable to detect an association between a specific HCV genotype, the entity of HCV replication, and type 2 diabetes. This finding may have been limited by the dispersion of the different HCV genotypes in the cohort and the proportion of missing values which may have reduced the power to detect an association. With these limitations in mind, our observations may suggest that the presence of HCV replication and not its entity or type is associated with diabetes, indicating an indirect pathogenetic role for HCV.
Other factors associated with type 2 diabetes, male sex, older age, higher baseline BMI, glucose and triglycerides, and hypertension are consistent with those found in other cohorts of HIV-infected and uninfected individuals. 21 Interestingly, we also found that regimens containing d-drugs were associated with a higher risk of diabetes, consistent with their higher metabolic impact. Similarly, a higher incidence was observed for the association of NRTI with unboosted PI, probably representing older regimens with PI showing a deeper impact on insulin resistance.
Our findings have a very strong practical implication. Indeed, HCV eradication, a goal which is now obtainable in the majority of HCV/HIV co-infected individuals, may result in an additional clinical benefit in this population. We found a 73% (95% CI: 8% to 178%) increase in incidence of diabetes in individuals with active HCV replication. Given the overall incidence in our study population, this translates in an incidence of approximately 1.5 per 100 PY of type 2 diabetes attributable to active HCV replication. Given the chronicity of type 2 diabetes and its clinical consequences and assuming that the majority of these cases could be averted by HCV eradication, HCV treatment in this population may result in a relevant benefit in terms of both patients and public health, not only because of the prevention of liver-related morbidity and mortality.
Another goal of the current study was to explore the association of latent CMV infection with type 2 diabetes. We found no association of positive CMV IgG serostatus neither with incident nor with prevalent type 2 diabetes. This is the first analysis of this kind in the HIV-infected population and its results are in contrast with some observation in the elderly HIV-uninfected population. 14 Although CMV-positive serostatus has been associated with increased immune activation in HIV, 13 the absence of any correlation with type 2 diabetes, in contrast to the observed association with active HCV replication, suggests that distinct immune-inflammatory mechanisms are triggered by these 2 very different chronic viral infections. However, because we could not analyze the plasma CMV DNA status, our observation does not exclude the role of active CMV replication in determining the risk of diabetes.
The results of this study should be interpreted with caution given its retrospective nature. However, in the ICONA cohort, this limitation is only partial, given the fact that patients are enrolled and followed prospectively and that the diagnosis of clinical events, including diabetes, is validated by an external monitor using standardized criteria.
In conclusion, in this large observational study, we found a significant association of active HCV replication with incident and prevalent type 2 diabetes. This result is consistent with previous observations in the HCV monoinfected population and with the hypothesized mechanism by which HCV may induce liver steatosis and insulin resistance. 
